Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.

MLA

Zeng, Bijun, et al. “Self-Adjuvanting Nanoemulsion Targeting Dendritic Cell Receptor Clec9A Enables Antigen-Specific Immunotherapy.” The Journal of Clinical Investigation, vol. 128, no. 5, May 2018, pp. 1971–84. EBSCOhost, https://doi.org/10.1172/JCI96791.

APA

Zeng, B., Middelberg, A. P., Gemiarto, A., MacDonald, K., Baxter, A. G., Talekar, M., Moi, D., Tullett, K. M., Caminschi, I., Lahoud, M. H., Mazzieri, R., Dolcetti, R., & Thomas, R. (2018). Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. The Journal of Clinical Investigation, 128(5), 1971–1984. https://doi.org/10.1172/JCI96791

Chicago

Zeng, Bijun, Anton Pj Middelberg, Adrian Gemiarto, Kelli MacDonald, Alan G Baxter, Meghna Talekar, Davide Moi, et al. 2018. “Self-Adjuvanting Nanoemulsion Targeting Dendritic Cell Receptor Clec9A Enables Antigen-Specific Immunotherapy.” The Journal of Clinical Investigation 128 (5): 1971–84. doi:10.1172/JCI96791.